PR
PRTA.NS
—
NSE (India)
Pharmaceuticals & Medical Research
Pratham EPC Projects Ltd
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$9,98
Open
$9,95
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Pratham EPC Projects Ltd is engaged in construction and engineering services within the industrial and commercial services sector.
Business. Pratham EPC Projects Ltd (PRTA.NS) is an Indian company operating in the pharmaceuticals and medical research industry. The firm is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic presence are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
HOLD6 analysts
3 buy2 hold1 sell
Avg 12m price target21,40
Analyst recommendations
6 analysts · consensus HoldBuy3
Hold2
Sell1
12-month price target
21,40
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
6 analysts · indicative
Ownership→
FMR LLC
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to PRTA.NS. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Pratham EPC Projects Ltd (PRTA.NS) is an Indian company operating in the pharmaceuticals and medical research industry. The firm is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic presence are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDPratham EPC Projects Ltd has a basic and diluted share count of 18,212,489 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
The company's profitability and return metrics are not available in the current dataset, making it difficult to compare its performance against industry benchmarks or preferred metrics for the construction and engineering sector. Without access to key profitability indicators such as EBITDA margins or ROIC, a detailed assessment of its financial health is constrained.
Segment and geographic exposure data are not disclosed in the available financial reports, limiting the ability to assess revenue concentration or geographic diversification. This lack of transparency could pose challenges in evaluating the company's resilience to regional economic shifts or sector-specific downturns.
Growth trajectory data is also not available in the current dataset, preventing a quantitative analysis of the company's revenue performance over time or its projected growth in the current and next fiscal years. Without historical or forward-looking revenue data, it is difficult to assess the company's market position or expansion potential.
The risk assessment indicates a low dilution risk, but the liquidity risk remains unassessed due to the lack of balance-sheet inputs and no going-concern language in the source documents. This absence of data could hinder the ability to evaluate the company's short-term financial obligations or its capacity to fund operations without external financing.
Recent events, including filings and transcripts, are not disclosed in the available data, limiting the ability to assess any material developments or strategic shifts that may have occurred recently. This lack of information could affect the understanding of the company's current operational and financial status.
Key takeaways
- Pratham EPC Projects Ltd has no immediate dilution pressure, with basic and diluted share counts aligned at 18,212,489 shares.
- The company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
- Profitability and return metrics are not available, making it difficult to compare the company's performance against industry benchmarks.
- Segment and geographic exposure data are not disclosed, limiting the ability to assess revenue concentration or geographic diversification.
- Growth trajectory data is not available, preventing a quantitative analysis of the company's revenue performance or projected growth.
- Recent events, including filings and transcripts, are not disclosed, limiting the ability to assess any material developments or strategic shifts.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation FY
Market price
$134,10
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships7 disclosed relationships · 2 types · extracted from filings & disclosures
Partners2
Bristol-myers Squibb CoBMY.OPartner95%Source ↗
Roche Holding AGROG.TOPartner95%Source ↗
Subsidiaries5
EX21:0364cb941d21EX21:0364cb941d21Subsidiarie97%
EX21:75a1733a5c54EX21:75a1733a5c54Subsidiarie97%
EX21:85c46a2ce45eEX21:85c46a2ce45eSubsidiarie97%
EX21:8b41d3205f46EX21:8b41d3205f46Subsidiarie97%
EX21:ca90e13f9cb3EX21:ca90e13f9cb3Subsidiarie97%
Supply chain
Vendors → PRTA ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison8 peers · vs PRTA · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
+127,5 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
+39,2 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
-73,2 vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
+92,1 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
+106,0 vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,61
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
+29,5 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
0,29
Predicted surprise
+0,00
Beat probability
45 %
Analysts
6
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-23 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$8,00
Mean$21,40
Median$20,00
High$36,00
Spot$134,10
−84.0 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 922 000 sh14 grants14 insiders
- Director · Stock Option (Right to Buy) → Ordinary SharesAcquired 27 000 @ $9,76grant · 2026-05-15
- Director · Stock Option (Right to Buy) → Ordinary SharesAcquired 27 000 @ $9,76grant · 2026-05-15
- Director · Stock Option (Right to Buy) → Ordinary SharesAcquired 27 000 @ $9,76grant · 2026-05-15
- Director · Stock Option (Right to Buy) → Ordinary SharesAcquired 27 000 @ $9,76grant · 2026-05-15
- Director · Stock Option (Right to Buy) → Ordinary SharesAcquired 27 000 @ $9,76grant · 2026-05-15
- Director · Stock Option (Right to Buy) → Ordinary SharesAcquired 27 000 @ $9,76grant · 2026-05-15
- Chief Strategy Officer · Stock Option (Right to Buy) → Ordinary SharesAcquired 100 000 @ $10,50grant · 2026-04-10
- Chief Accounting Officer · Stock Option (Right to Buy) → Ordinary SharesAcquired 150 000 @ $9,36grant · 2026-03-03
- Chief Scientific Officer · Stock Option (Right to Buy) → Ordinary SharesAcquired 190 000 @ $9,36grant · 2026-03-03
- Chief Legal Officer · Stock Option (Right to Buy) → Ordinary SharesAcquired 190 000 @ $9,36grant · 2026-03-03
- Chief Development Officer · Stock Option (Right to Buy) → Ordinary SharesAcquired 190 000 @ $9,36grant · 2026-03-03
- Chief Operating Officer · Stock Option (Right to Buy) → Ordinary SharesAcquired 190 000 @ $9,36grant · 2026-03-03
- Chief Strategy Officer and CFO · Stock Option (Right to Buy) → Ordinary SharesAcquired 230 000 @ $9,36grant · 2026-03-03
- Director, President and CEO · Stock Option (Right to Buy) → Ordinary SharesAcquired 520 000 @ $9,36grant · 2026-03-03
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Source documents
- Pratham EPC Projects Ltd Market data — financials · 2026-05-29
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,00 %$73M
- Investment Managers · as of 2024-06-300,00 %$80M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$19M
- Investment Managers · as of 2024-12-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$20M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Leadership
- Gene G. KinneyPresident, Chief Executive Officer, Director
Insider activity
Net buying5 buys · 0 sellsnet $3,1M1 insiders · last 365d
- 10% owner · Ordinary Shares, par value $0.01 per shareBought 20 000 @ $7,90$158K · 2026-06-16
- 10% owner · Ordinary Shares, par value $0.01 per shareOther 325 000 · 2026-06-15
- 10% owner · Ordinary Shares, par value $0.01 per shareBought 125 000 @ $8,17$1,0M · 2026-06-11
- 10% owner · Ordinary Shares, par value $0.01 per shareBought 50 000 @ $9,31$465K · 2026-06-04
- 10% owner · Ordinary Shares, par value $0.01 per shareBought 50 000 @ $9,43$471K · 2026-06-02
- 10% owner · Ordinary Shares, par value $0.01 per shareBought 100 000 @ $9,81$981K · 2026-05-22
Short positioning
8.2Mshares short-2.1% vs prior
16.4days to cover
72.1%short of daily vol
397fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
PRTA.NSCanonical
NSE (India) · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskUnknown
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -99.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -99.6%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -34.8%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -39.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -9.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -23.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -40.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -42.4%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -92.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -99.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -38.9%Derived (calculated)
- Net margin (FY 2025-12-31): -2,520.6%Derived (calculated)
- Return on equity (FY 2025-12-31): -87.0%Derived (calculated)
- Return on assets (FY 2025-12-31): -74.7%Derived (calculated)
- Current ratio (FY 2025-12-31): 7.72xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.17xDerived (calculated)
- Net income (annual): USD -244.09MSEC XBRL filing
- Revenue (annual): USD 9.68MSEC XBRL filing
- R&D expense (annual): USD 134.85MSEC XBRL filing
- Shares outstanding (annual): 53.83MSEC XBRL filing
- Shareholders' equity (annual): USD 280.47MSEC XBRL filing
- Total assets (annual): USD 326.8MSEC XBRL filing
- Operating cash flow (annual): USD -163.58MSEC XBRL filing
- Current liabilities (annual): USD 40.84MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-08-03EVENTQ2 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-16 00:00 UTCINSIDER5 insider transactions — 2026-06 · net buy $2.1M
2026-06-16INSIDERSCULLY WILLIAM P bought 20.0k sh Ordinary Shares, par value $0.01 per share — 10% owner ~$158k
2026-06-15INSIDERSCULLY WILLIAM P transacted 325.0k sh Ordinary Shares, par value $0.01 per share — 10% owner
2026-06-11INSIDERSCULLY WILLIAM P bought 125.0k sh Ordinary Shares, par value $0.01 per share — 10% owner ~$1.02M
2026-06-04INSIDERSCULLY WILLIAM P bought 50.0k sh Ordinary Shares, par value $0.01 per share — 10% owner ~$465k
2026-06-02INSIDERSCULLY WILLIAM P bought 50.0k sh Ordinary Shares, par value $0.01 per share — 10% owner ~$471k
2026-05-22 00:00 UTCINSIDER7 insider transactions — 2026-05 · net buy $981k 6 derivative
2026-05-22INSIDERSCULLY WILLIAM P bought 100.0k sh Ordinary Shares, par value $0.01 per share — 10% owner ~$981k
2026-05-15INSIDERCOLLIER RICHARD T acquired 27.0k sh Stock Option (Right to Buy) — Director
2026-05-15INSIDERWELCH DANIEL G acquired 27.0k sh Stock Option (Right to Buy) — Director
2026-05-15INSIDERSelkoe Dennis J. acquired 27.0k sh Stock Option (Right to Buy) — Director
2026-05-15INSIDEREkman Lars acquired 27.0k sh Stock Option (Right to Buy) — Director
2026-05-15INSIDERDunn William H. Jr. acquired 27.0k sh Stock Option (Right to Buy) — Director
2026-05-15INSIDERCooke Shane acquired 27.0k sh Stock Option (Right to Buy) — Director
2026-04-10 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative
2026-04-10INSIDERKingston Anne Evans acquired 100.0k sh Stock Option (Right to Buy) — Chief Strategy Officer
2026-03-03 00:00 UTCINSIDER7 insider transactions — 2026-03 7 derivative
2026-03-03INSIDERZago Wagner M. acquired 190.0k sh Stock Option (Right to Buy) — Chief Scientific Officer
2026-03-03INSIDERWalker Karin L acquired 150.0k sh Stock Option (Right to Buy) — Chief Accounting Officer
2026-03-03INSIDERNguyen Tran acquired 230.0k sh Stock Option (Right to Buy) — Chief Strategy Officer and CFO
2026-03-03INSIDERSmith Brandon S. acquired 190.0k sh Stock Option (Right to Buy) — Chief Operating Officer
2026-03-03INSIDERSwanson Chad J. acquired 190.0k sh Stock Option (Right to Buy) — Chief Development Officer
2026-03-03INSIDERKinney Gene G. acquired 520.0k sh Stock Option (Right to Buy) — Director, President and CEO
2026-03-03INSIDERMalecek Michael J acquired 190.0k sh Stock Option (Right to Buy) — Chief Legal Officer
Showing the 40 most recent of 45 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage